Most Read Articles
2 days ago
Higher values of plasma aldosterone concentration (PAC) show a robust association with some metabolic variables, including triglycerides, urinary albumin excretion (UAE), carotid intima-media thickness (cIMT), worse ankle-brachial index (ABI) and major prevalence of carotid plaques, a recent study has shown.
24 Sep 2019
Obese patients are exposed to greater doses of radiation during radiofrequency ablation for atrial fibrillation, a recent study has found.
01 Oct 2019
Patients with greater ischaemia who underwent positron emission tomography (PET) myocardial perfusion imaging (MPI) have better survival with early revascularization, reports a study. Exploratory analyses reveal a lower threshold than that previously reported for single-photon emission computed tomography (SPECT).

Original New Drug Application Approvals by US FDA (01 - 15 July 2019)

15 Jul 2019
New drug applications approved by US FDA as of 01 - 15 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

XPOVIO
  • Active Ingredient(s): Selinexor
  • Strength: 20 mg
  • Dosage Form(s) / Route(s): Tablet; oral
  • Company: Karyopharm Therapeutics Inc.
  • Approval Date: 03 July 2019
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
  • Approved Label03 July 2019 (PDF)

KATERZIA
  • Active Ingredient(s): Amlodipine benzoate
  • Strength: 1 mg/mL
  • Dosage Form(s) / Route(s): Suspension; oral
  • Company: Silvergate Pharms
  • Approval Date: 08 July 2019
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): May be used alone or in combination with other antihypertensive and antianginal agents for the treatment of:
    • Hypertension: indicated for the treatment of hypertension in adults and children 6 years and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily stroke and myocardial infarctions.
    • Coronary Artery Disease: Chronic Stable Angina; Vasospastic Angina (Prinzmetal's or Variant Angina); Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction <40%.
  • Approved Label08 July 2019 (PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Higher values of plasma aldosterone concentration (PAC) show a robust association with some metabolic variables, including triglycerides, urinary albumin excretion (UAE), carotid intima-media thickness (cIMT), worse ankle-brachial index (ABI) and major prevalence of carotid plaques, a recent study has shown.
24 Sep 2019
Obese patients are exposed to greater doses of radiation during radiofrequency ablation for atrial fibrillation, a recent study has found.
01 Oct 2019
Patients with greater ischaemia who underwent positron emission tomography (PET) myocardial perfusion imaging (MPI) have better survival with early revascularization, reports a study. Exploratory analyses reveal a lower threshold than that previously reported for single-photon emission computed tomography (SPECT).